Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of new PET tracers for lung cancer.
Szyszko TA, Yip C, Szlosarek P, Goh V, Cook GJ. Szyszko TA, et al. Lung Cancer. 2016 Apr;94:7-14. doi: 10.1016/j.lungcan.2016.01.010. Epub 2016 Jan 21. Lung Cancer. 2016. PMID: 26973200 Review.
PET/CT and PET/MRI in head and neck malignancy.
Szyszko TA, Cook GJR. Szyszko TA, et al. Clin Radiol. 2018 Jan;73(1):60-69. doi: 10.1016/j.crad.2017.09.001. Epub 2017 Oct 10. Clin Radiol. 2018. PMID: 29029767 Review.
The ability of post-chemoradiotherapy DWI ADCmean and 18F-FDG SUVmax to predict treatment outcomes in head and neck cancer: impact of human papilloma virus oropharyngeal cancer status.
Connor S, Sit C, Anjari M, Lei M, Guerrero-Urbano T, Szyszko T, Cook G, Bassett P, Goh V. Connor S, et al. J Cancer Res Clin Oncol. 2021 Aug;147(8):2323-2336. doi: 10.1007/s00432-021-03662-y. Epub 2021 Jun 22. J Cancer Res Clin Oncol. 2021. PMID: 34159420 Free PMC article.
Palatine tonsil SUVmax on FDG PET-CT as a discriminator between benign and malignant tonsils in patients with and without head and neck squamous cell carcinoma of unknown primary.
Pencharz D, Dunn J, Connor S, Siddiqui A, Sriskandan N, Thavaraj S, Jeannon JP, Oakley R, Lei M, Guerrero-Urbano T, Cook GJ, Szyszko TA. Pencharz D, et al. Among authors: szyszko ta. Clin Radiol. 2019 Feb;74(2):165.e17-165.e23. doi: 10.1016/j.crad.2018.10.007. Epub 2018 Nov 16. Clin Radiol. 2019. PMID: 30454841
Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.
Szyszko TA, Dunn JT, Phillips MM, Bomalaski J, Sheaff MT, Ellis S, Pike L, Goh V, Cook GJR, Szlosarek PW. Szyszko TA, et al. JTO Clin Res Rep. 2022 Jul 20;3(9):100382. doi: 10.1016/j.jtocrr.2022.100382. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36082278 Free PMC article.
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW. Beddowes E, et al. J Clin Oncol. 2017 Jun 1;35(16):1778-1785. doi: 10.1200/JCO.2016.71.3230. Epub 2017 Apr 7. J Clin Oncol. 2017. PMID: 28388291 Free PMC article. Clinical Trial.
Optimizing arginine deprivation for hard-to-treat cancers.
Khadeir R, Szyszko T, Szlosarek PW. Khadeir R, et al. Oncotarget. 2017 Oct 27;8(57):96468-96469. doi: 10.18632/oncotarget.22099. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228540 Free PMC article. No abstract available.
39 results